Dirk Pleimes
Chief Executive Officer Myelo Therapeutics GmbH
Dr. Dirk Pleimes is Group CEO & CMO of Pentixapharm Holding AG, a clinical-stage radiopharmaceutical company focused on theranostic innovation. He has a background in strategic, scientific and medical leadership, having co-founded and led biotech and pharma ventures and held research & clinical development roles across disciplines. Since April 2025, he formally assumed the CEO role while continuing his responsibilities as CMO.
Seminars
Wednesday 25th February 2026
Translating Immuno-Oncology Targets into Radioligand Precision Platforms
11:30 am
- Exploring how integrating antibody engineering with radioligand design enables precise delivery of therapeutic isotopes to immune-relevant tumor environments
- Showcasing how emerging immune-regulatory targets beyond PD-(L)1 offer novel pathways for targeted radioligand modulation
- Analyzing tumor-restricted glycoproteins as highly specific anchors for next-generation theranostic development
New Company for 2026
